The unique characteristics of autoantibodies, produced in early stages of disease and persisting throughout the course, make them promising tools for early identification of disease and for optimizing treatment.

Autoantibody biomarkers identified and validated using Sengenics protein arrays have shown utility across a range of diseases—from autoimmune and neuroinflammatory diseases to cancers and infectious diseases.

Learn more about disease applications for Sengenics technology and services.